This week from Drug Target Review...
EDITOR'S PICK
New treatment for MS using artificial nerve fibres
MS is an autoimmune disease in which the body’s own immune cells attack myelin in the brain and spinal cord. When myelin is broken down, the impulses are either transferred more slowly or not at all, and this leads to functional impairment, or even loss, for the patient.
Danish researchers undertake a new project that aims to find new forms of treatment for diseases such as MS, which breaks down myelin and nerve fibres, by developing new, artificial nerve fibres. Read more>>>
===
TRENDING THIS WEEK
Researchers develop novel method to insert large DNA sequences more accurately in cells
The scientists say that the engineered CRISPR enzymes could overcome key limitations for eventual use to treat genetic diseases irrespective of a patient’s particular mutation. Read more>>>
Unexpected neuronal molecule makes prostate cancer more aggressive
UUS researchers discover a potential therapeutic avenue through the molecule NgR2, against an aggressive form of prostate cancer. Read more>>>
2023 and beyond: revolutionising drug discovery
In this exclusive article, Dr Menetski shares his foresights into 2023 drug discovery trends and how we can change the way we research. Read more>>>
Artificial intelligence: a great crash of hype into reality
In this article, Aaron Daugherty, Aria Pharmaceuticals, highlights how the industry can use AI to transform research. Read more>>>
===
WHAT TO LISTEN TO
Episode 16 – Data acquisition of organoids
Tune into this podcast to hear experts discuss imaging and obtaining data from organoids!
In this episode, sponsored by Molecular Devices, we cover the advantages of three-dimensional imaging over two-dimensional and how to obtain quality data from organoids.
===
WHAT TO WATCH
Ranging from decoding cancer inflammation to engineering cell lines and everything in between - discover our range of upcoming live webinars and on-demand sessions which are completely FREE to join.
===
JOIN THE COMMUNITY
Get your FREE subscription to Drug Target Review to stay up to date with the most pressing topics and trends in drug discovery and early-phase therapeutic development.
Cut down on screen time by listening to our podcasts, get intimate during our webinars or sip a cup of coffee whilst flicking through our journal. As a member, you’ll also gain exclusive access to:
- Breaking news and features
- Invitations to member only events
- Unlimited archive of whitepapers, ebooks, past issues and much more…
We provide compelling content contributed by the world's most respected scientists, key opinion leaders and influencers.
